Synbiotic-driven modulation of the gut microbiota and metabolic functions related to obesity: insights from a human gastrointestinal model
Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastr...
Saved in:
| Published in | BMC microbiology Vol. 25; no. 1; pp. 250 - 15 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
27.04.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. |
|---|---|
| AbstractList | Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⸠CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. Keywords: Synbiotic, Limosilactobacillus reuteri KUB-AC5, Wolffia globosa, Gut microbiota, Obesity, In vitro gastrointestinal model Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management.Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⸠CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae . Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods ( p < 0.05). Additionally, butyrate levels significantly increased ( p < 0.05), while p -cresol, a deleterious metabolite, significantly decreased ( p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. Abstract Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study evaluated the effects of Limosilactobacillus reuteri KUB-AC5 (10⁸ CFU) and Wolffia globosa powder (6 g/day) using an in vitro continuous human gastrointestinal model. Fecal samples from obese donors were used to simulate the ascending and descending colon, with microbial viability, diversity, and metabolite production assessed over 14 days via culture-dependent and culture-independent methods. Synbiotic supplementation increased anaerobic bacterial counts by 2.6 log CFU/mL in the ascending colon and 2.2 log CFU/mL in the descending colon, with notable increases in lactic acid bacteria and reductions in Enterobacteriaceae. Metagenomic analysis revealed an increasing trend in microbial diversity and evenness after 7 days of treatment, though the changes were not statistically significant. PERMANOVA analysis confirmed significant shift in microbial community composition between stabilization, treatment, and washout periods (p < 0.05). Additionally, butyrate levels significantly increased (p < 0.05), while p-cresol, a deleterious metabolite, significantly decreased (p < 0.05). Bile acid composition was modulated, with increased tertiary bile acid 3-oxo-LCA and enhanced bile acid deconjugation, suggesting improved lipid metabolism and potential weight management benefits. These findings highlight the potential of synbiotic supplementation to enhance beneficial bacterial populations, improve microbial diversity, and support metabolic health in obesity management. |
| ArticleNumber | 250 |
| Audience | Academic |
| Author | Nagai, Kenshiro Vongsangnak, Wanwipa Wanikorn, Bandhita Nitisinprasert, Sunee Nakayama, Jiro Torrungruang, Pitchsupang Charoensiddhi, Suvimol Mok, Kevin Tomtong, Putsawee Nakphaichit, Massalin Ogawa, Takuma |
| Author_xml | – sequence: 1 givenname: Kevin surname: Mok fullname: Mok, Kevin – sequence: 2 givenname: Putsawee surname: Tomtong fullname: Tomtong, Putsawee – sequence: 3 givenname: Takuma surname: Ogawa fullname: Ogawa, Takuma – sequence: 4 givenname: Kenshiro surname: Nagai fullname: Nagai, Kenshiro – sequence: 5 givenname: Pitchsupang surname: Torrungruang fullname: Torrungruang, Pitchsupang – sequence: 6 givenname: Suvimol surname: Charoensiddhi fullname: Charoensiddhi, Suvimol – sequence: 7 givenname: Jiro surname: Nakayama fullname: Nakayama, Jiro – sequence: 8 givenname: Bandhita surname: Wanikorn fullname: Wanikorn, Bandhita – sequence: 9 givenname: Sunee surname: Nitisinprasert fullname: Nitisinprasert, Sunee – sequence: 10 givenname: Wanwipa surname: Vongsangnak fullname: Vongsangnak, Wanwipa – sequence: 11 givenname: Massalin surname: Nakphaichit fullname: Nakphaichit, Massalin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40289100$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkstu1DAUhiNURC_wAiyQJTawSPE1cdhUVcVlpEpIFNbWiWNnPErsYjsVfQWeGk-nlA5CXtiyv_Mf-_d_XB344E1VvST4lBDZvEuEyqapMRU1Zp1gNXlSHRHekpoSiQ8erQ-r45Q2GJNWsvZZdcgxlR3B-Kj6dXXrexey0_UQ3Y3xaA7DMkF2waNgUV4bNC4ZzU7HsAUBgR_QbDL0YXIa2cXrLZxQNKXMDCgHFHqTXL59j5xPblznhGwMMwK0XmbwaISUY3A-m5Sdh2nb00zPq6cWpmRe3M8n1fePH75dfK4vv3xaXZxf1loIkuteSEsYk5o2UmjDGw68tW0vTdN2otdyoHQAA5QJ6DVwjltOmcS4lVxTa9lJtdrpDgE26jq6GeKtCuDU3UaIo4JYDJmMYn2HuRFQZsqpFB2T1A6i76EbZMtl0TrbaV0v_WwGbXyOMO2J7p94t1ZjuFGEYsZJ2xSFN_cKMfxYiiFqdkmbaQJvwpIUI50ol-dyi77-B92EJRb_CkUxEUwQKv5SI5QXOG9Daay3ouq8_D4vHKOFOv0PVcZgyleXnFlX9vcK3u4VFCabn3mEJSW1uvq6z7567MqDHX9iVwC6A0qoUorGPiAEq2221S7bqmRb3WVbEfYbATLrXw |
| Cites_doi | 10.1016/j.tifs.2023.06.013 10.1038/nature11550 10.1016/j.jff.2021.104597 10.1016/j.beem.2021.101493 10.1002/fbe2.12002 10.1016/j.lfs.2020.118292 10.7717/peerj.32 10.7717/peerj.12158 10.1002/mco2.420 10.3390/horticulturae10111171 10.1016/j.fufo.2025.100608 10.3390/jof7090748 10.1016/j.molmed.2021.12.006 10.3390/microorganisms12020234 10.1128/AEM.66.6.2502-2512.2000 10.1080/19490976.2015.1127483 10.3390/toxins12040245 10.3390/biology11020294 10.1002/mnfr.202200649 10.3389/fendo.2024.1277921 10.1093/nar/gkt1244 10.1098/rsob.230014 10.1186/s40168-021-01101-1 10.3920/BM2018.0034 10.1080/19490976.2019.1650997 10.3390/foods12142647 10.3390/microorganisms9091900 10.1101/074161 10.1038/nbt.3960 10.1080/17446651.2020.1719068 10.1016/j.freeradbiomed.2015.04.004 10.1016/j.ejphar.2015.03.040 10.3389/fcimb.2024.1401462 10.2337/dc09-S355 10.1038/nmeth.2604 10.3390/foods11162438 10.1016/j.femsec.2004.05.002 10.1007/s00284-020-02124-x 10.3390/nu15081863 10.1093/bioinformatics/btq461 10.1128/msphere.00446-22 10.3920/BM2017.0164 10.20517/mrr.2022.15 10.1016/j.cell.2018.08.041 10.1080/19490976.2023.2172671 10.1016/j.pop.2015.10.001 10.1038/s41598-024-53912-5 10.3390/microorganisms9040697 10.1038/nrgastro.2017.75 10.1038/s41392-022-00974-4 10.3390/nu11030635 10.1007/BF00228615 10.3389/fmicb.2018.01685 10.1007/s13213-009-0004-9 10.1016/j.micres.2023.127336 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7QL 7T7 7U9 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12866-025-03953-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale in Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1471-2180 |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_3b904e5a3b9242859382fd5bba9d8748 PMC12034176 A837415332 40289100 10_1186_s12866_025_03953_1 |
| Genre | Journal Article |
| GeographicLocations | Thailand California United States Massachusetts Germany |
| GeographicLocations_xml | – name: Thailand – name: California – name: Germany – name: United States – name: Massachusetts |
| GrantInformation_xml | – fundername: Kasetsart University Research and Development Institute (KURDI) under the research topic "Center for Microbiota Innovation: Empowering Health via Probiotics, Prebiotics, Postbiotics, and Functional Products" grantid: FF(KU)51.67 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 7X7 88E 8FE 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IGS IHR INH INR ISR ITC KQ8 LK5 LK8 M1P M7P M7R MM. M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB ~02 CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB PMFND 3V. 7QL 7T7 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. M48 M7N P64 PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c551t-b58f1338c2685ce464a47f7b8e6795bc8d22daea235abca4407423800784c2ff3 |
| IEDL.DBID | DOA |
| ISSN | 1471-2180 |
| IngestDate | Wed Aug 27 01:34:36 EDT 2025 Thu Aug 21 18:26:59 EDT 2025 Fri Jul 11 18:31:41 EDT 2025 Fri Jul 25 09:18:02 EDT 2025 Tue Jun 17 21:58:17 EDT 2025 Fri Jun 06 06:59:29 EDT 2025 Fri Jun 27 05:13:03 EDT 2025 Mon Jul 21 05:26:04 EDT 2025 Sun Jul 06 05:06:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Gut microbiota Obesity In vitro gastrointestinal model Synbiotic Wolffia globosa Limosilactobacillus reuteri KUB-AC5 |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c551t-b58f1338c2685ce464a47f7b8e6795bc8d22daea235abca4407423800784c2ff3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/3b904e5a3b9242859382fd5bba9d8748 |
| PMID | 40289100 |
| PQID | 3201535125 |
| PQPubID | 42585 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3b904e5a3b9242859382fd5bba9d8748 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12034176 proquest_miscellaneous_3195800486 proquest_journals_3201535125 gale_infotracmisc_A837415332 gale_infotracacademiconefile_A837415332 gale_incontextgauss_ISR_A837415332 pubmed_primary_40289100 crossref_primary_10_1186_s12866_025_03953_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-04-27 |
| PublicationDateYYYYMMDD | 2025-04-27 |
| PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-27 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC microbiology |
| PublicationTitleAlternate | BMC Microbiol |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | I Julia (3953_CR20) 2023; 2 J Ji (3953_CR2) 2023; 4 P Boonarsa (3953_CR15) 2024; 10 VT Pham (3953_CR19) 2018; 9 J Jiang (3953_CR50) 2010; 60 M Vijayasarathy (3953_CR47) 2020; 77 AK Mishra (3953_CR39) 2020; 261 H Tanaka (3953_CR49) 2000; 66 3953_CR27 L Lahti (3953_CR56) 2013; 1 JM Ridlon (3953_CR51) 2016; 7 GR Gibson (3953_CR8) 2017; 14 K Abarenkov (3953_CR29) 2020; 4 3953_CR32 K Mok (3953_CR10) 2024; 14 3953_CR33 ML Graham (3953_CR21) 2015; 759 3953_CR34 K Hou (3953_CR41) 2022; 7 K Molly (3953_CR17) 1993; 39 3953_CR36 N Zmora (3953_CR55) 2018; 174 3953_CR37 W Sathitkowitchai (3953_CR57) 2021; 9 B Krawczyk (3953_CR38) 2021; 9 S Buddhasiri (3953_CR9) 2022; 27 M Daniali (3953_CR5) 2020; 15 CA Lozupone (3953_CR35) 2012; 489 M Tanaka (3953_CR30) 2020; 11 RC Edgar (3953_CR25) 2010; 26 RC Edgar (3953_CR26) 2013; 10 G Glorieux (3953_CR59) 2020; 12 AB Larabi (3953_CR43) 2023; 15 JR Cole (3953_CR28) 2014; 42 N on-nom (3953_CR12) 2023; 12 W Campos-Perez (3953_CR58) 2021; 1866 C Diotallevi (3953_CR13) 2021; 84 Y Qi (3953_CR18) 2023; 270 LM Ney (3953_CR40) 2023; 13 3953_CR44 M Andriamihaja (3953_CR45) 2015; 85 N On-Nom (3953_CR14) 2023; 12 3953_CR3 T Ma (3953_CR31) 2023; 138 M Nakphaichit (3953_CR11) 2019; 10 Y-L Shen (3953_CR4) 2022; 1 3953_CR6 3953_CR7 GA Stuivenberg (3953_CR46) 2022; 7 3953_CR1 DV Guzior (3953_CR48) 2021; 9 K Mok (3953_CR24) 2021; 7 PI Costea (3953_CR23) 2017; 35 Y Ma (3953_CR52) 2023; 67 R Li (3953_CR53) 2021; 35 S Possemiers (3953_CR22) 2004; 49 B Staels (3953_CR42) 2009; 32 3953_CR16 MM Thibaut (3953_CR54) 2022; 28 |
| References_xml | – volume: 138 start-page: 178 year: 2023 ident: 3953_CR31 publication-title: Trends Food Sci Technol doi: 10.1016/j.tifs.2023.06.013 – volume: 489 start-page: 220 issue: 7415 year: 2012 ident: 3953_CR35 publication-title: Nature doi: 10.1038/nature11550 – volume: 84 start-page: 104597 year: 2021 ident: 3953_CR13 publication-title: J Funct Foods doi: 10.1016/j.jff.2021.104597 – volume: 35 start-page: 101493 issue: 3 year: 2021 ident: 3953_CR53 publication-title: Best Pract Res Clin Endocrinol Metab doi: 10.1016/j.beem.2021.101493 – volume: 1866 start-page: 158900 issue: 5 year: 2021 ident: 3953_CR58 publication-title: Biochim Et Biophys Acta (BBA) - Mol Cell Biology Lipids – volume: 1 start-page: 101 issue: 1 year: 2022 ident: 3953_CR4 publication-title: Food Bioeng doi: 10.1002/fbe2.12002 – volume: 4 start-page: 2020 year: 2020 ident: 3953_CR29 publication-title: Version – volume: 261 start-page: 118292 year: 2020 ident: 3953_CR39 publication-title: Life Sci doi: 10.1016/j.lfs.2020.118292 – volume: 1 start-page: e32 year: 2013 ident: 3953_CR56 publication-title: PeerJ doi: 10.7717/peerj.32 – volume: 9 start-page: e12158 year: 2021 ident: 3953_CR57 publication-title: PeerJ doi: 10.7717/peerj.12158 – volume: 4 start-page: e420 issue: 6 year: 2023 ident: 3953_CR2 publication-title: MedComm (2020) doi: 10.1002/mco2.420 – volume: 10 start-page: 1171 issue: 11 year: 2024 ident: 3953_CR15 publication-title: Horticulturae doi: 10.3390/horticulturae10111171 – ident: 3953_CR16 doi: 10.1016/j.fufo.2025.100608 – volume: 7 start-page: 748 issue: 9 year: 2021 ident: 3953_CR24 publication-title: J Fungi doi: 10.3390/jof7090748 – volume: 28 start-page: 223 issue: 3 year: 2022 ident: 3953_CR54 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2021.12.006 – ident: 3953_CR32 doi: 10.3390/microorganisms12020234 – volume: 66 start-page: 2502 issue: 6 year: 2000 ident: 3953_CR49 publication-title: Appl Environ Microbiol doi: 10.1128/AEM.66.6.2502-2512.2000 – volume: 7 start-page: 22 issue: 1 year: 2016 ident: 3953_CR51 publication-title: Gut Microbes doi: 10.1080/19490976.2015.1127483 – volume: 12 start-page: 245 issue: 4 year: 2020 ident: 3953_CR59 publication-title: Toxins doi: 10.3390/toxins12040245 – ident: 3953_CR44 doi: 10.3390/biology11020294 – volume: 67 start-page: e2200649 issue: 10 year: 2023 ident: 3953_CR52 publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.202200649 – ident: 3953_CR6 doi: 10.3389/fendo.2024.1277921 – volume: 42 start-page: D633 issue: D1 year: 2014 ident: 3953_CR28 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkt1244 – volume: 13 start-page: 230014 issue: 3 year: 2023 ident: 3953_CR40 publication-title: Open Biol doi: 10.1098/rsob.230014 – volume: 9 start-page: 140 issue: 1 year: 2021 ident: 3953_CR48 publication-title: Microbiome doi: 10.1186/s40168-021-01101-1 – volume: 10 start-page: 43 issue: 1 year: 2019 ident: 3953_CR11 publication-title: Beneficial Microbes doi: 10.3920/BM2018.0034 – volume: 11 start-page: 205 issue: 2 year: 2020 ident: 3953_CR30 publication-title: Gut Microbes doi: 10.1080/19490976.2019.1650997 – volume: 12 start-page: 2647 issue: 14 year: 2023 ident: 3953_CR14 publication-title: Foods doi: 10.3390/foods12142647 – volume: 9 start-page: 1900 issue: 9 year: 2021 ident: 3953_CR38 publication-title: Microorganisms doi: 10.3390/microorganisms9091900 – ident: 3953_CR27 doi: 10.1101/074161 – volume: 27 start-page: APST issue: 02 year: 2022 ident: 3953_CR9 publication-title: Asia-Pacific J Sci Technol – volume: 35 start-page: 1069 issue: 11 year: 2017 ident: 3953_CR23 publication-title: Nat Biotechnol doi: 10.1038/nbt.3960 – volume: 15 start-page: 1 issue: 1 year: 2020 ident: 3953_CR5 publication-title: Expert Rev Endocrinol Metabolism doi: 10.1080/17446651.2020.1719068 – volume: 85 start-page: 219 year: 2015 ident: 3953_CR45 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2015.04.004 – volume: 759 start-page: 19 year: 2015 ident: 3953_CR21 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2015.03.040 – ident: 3953_CR34 doi: 10.3389/fcimb.2024.1401462 – volume: 32 start-page: S237 issue: Suppl 2 year: 2009 ident: 3953_CR42 publication-title: Diabetes Care doi: 10.2337/dc09-S355 – volume: 10 start-page: 996 issue: 10 year: 2013 ident: 3953_CR26 publication-title: Nat Methods doi: 10.1038/nmeth.2604 – ident: 3953_CR36 doi: 10.3390/foods11162438 – volume: 49 start-page: 495 issue: 3 year: 2004 ident: 3953_CR22 publication-title: FEMS Microbiol Ecol doi: 10.1016/j.femsec.2004.05.002 – volume: 77 start-page: 3000 issue: 10 year: 2020 ident: 3953_CR47 publication-title: Curr Microbiol doi: 10.1007/s00284-020-02124-x – ident: 3953_CR7 doi: 10.3390/nu15081863 – volume: 12 start-page: 2647 year: 2023 ident: 3953_CR12 publication-title: Foods doi: 10.3390/foods12142647 – volume: 26 start-page: 2460 issue: 19 year: 2010 ident: 3953_CR25 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq461 – volume: 7 start-page: e0044622 issue: 6 year: 2022 ident: 3953_CR46 publication-title: mSphere doi: 10.1128/msphere.00446-22 – volume: 9 start-page: 725 issue: 5 year: 2018 ident: 3953_CR19 publication-title: Beneficial Microbes doi: 10.3920/BM2017.0164 – volume: 2 start-page: 2 issue: 1 year: 2023 ident: 3953_CR20 publication-title: Microbiome Res Rep doi: 10.20517/mrr.2022.15 – volume: 174 start-page: 1388 issue: 6 year: 2018 ident: 3953_CR55 publication-title: Cell doi: 10.1016/j.cell.2018.08.041 – volume: 15 start-page: 2172671 issue: 1 year: 2023 ident: 3953_CR43 publication-title: Gut Microbes doi: 10.1080/19490976.2023.2172671 – ident: 3953_CR1 doi: 10.1016/j.pop.2015.10.001 – volume: 14 start-page: 4730 issue: 1 year: 2024 ident: 3953_CR10 publication-title: Sci Rep doi: 10.1038/s41598-024-53912-5 – ident: 3953_CR33 doi: 10.3390/microorganisms9040697 – volume: 14 start-page: 491 issue: 8 year: 2017 ident: 3953_CR8 publication-title: Nat Reviews Gastroenterol Hepatol doi: 10.1038/nrgastro.2017.75 – volume: 7 start-page: 135 issue: 1 year: 2022 ident: 3953_CR41 publication-title: Signal Transduct Target Therapy doi: 10.1038/s41392-022-00974-4 – ident: 3953_CR3 doi: 10.3390/nu11030635 – volume: 39 start-page: 254 issue: 2 year: 1993 ident: 3953_CR17 publication-title: Appl Microbiol Biotechnol doi: 10.1007/BF00228615 – ident: 3953_CR37 doi: 10.3389/fmicb.2018.01685 – volume: 60 start-page: 81 issue: 1 year: 2010 ident: 3953_CR50 publication-title: Ann Microbiol doi: 10.1007/s13213-009-0004-9 – volume: 270 start-page: 127336 year: 2023 ident: 3953_CR18 publication-title: Microbiol Res doi: 10.1016/j.micres.2023.127336 |
| SSID | ssj0017837 |
| Score | 2.4286146 |
| Snippet | Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This study... Abstract Synbiotic interventions have gained increasing attention for modulating gut microbiota and metabolic functions in obesity-related disorders. This... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 250 |
| SubjectTerms | Adult Bacteria Bacteria - classification Bacteria - genetics Bacteria - isolation & purification Bacteria - metabolism Bile acids Body weight Care and treatment Cholesterol Colon Community composition Complications and side effects Composition Cresols Culture Development and progression Dietary supplements Digestive system Dosage and administration Feces Feces - microbiology Female Fermentation Gastrointestinal Microbiome Gastrointestinal tract Gastrointestinal Tract - metabolism Gastrointestinal Tract - microbiology Gut microbiota Humans In vitro gastrointestinal model Inflammation Intestinal microflora Laboratories Lactic acid Lactic acid bacteria Limosilactobacillus reuteri - growth & development Limosilactobacillus reuteri KUB-AC5 Lipid metabolism Lipids Male Medical research Medicine, Experimental Metabolic diseases Metabolism Metabolites Metagenomics Microbial Viability Microbiota Microbiota (Symbiotic organisms) Microorganisms Nitrogen Obesity Obesity - metabolism Obesity - microbiology Physiological aspects Prebiotics Probiotics Small intestine Statistical analysis Synbiotic Synbiotics - administration & dosage Wolffia globosa |
| SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Li9RAEG50RfAivo2u0orgQcIm_UrHi6zisgp6cF2YW9OvjANOsk4yh_0L_mqrOplxg-ApkK5AJ1Vdj3T19xHyKrrC1xx3dYNzuVDB5rWSPBeV47EqWaxTt_uXr-r0XHxeyMX0w62f2ip3PjE56tB5_Ed-xCFSSQ7hSb67-JUjaxTurk4UGtfJDYQuQ6uuFvuCq6yg-todlNHqqAdfrLDlVuYFr2FC5SwYJcz-fz3zldA0b5u8EodO7pDbUwJJj0eN3yXXYnuP3BwpJS_vk99nl61bdTCYhw16MrruwkTRRbuGQr5Hl9uBrlcjAtNgqW0DXccBrOHnylMMdMkWaTrmEgMdOtqN9AFv6artsZrvKR5LoZYmij-6tP2w6RB5AhwGzi7x6zwg5ycfv384zSe-hdxD3jTkTuoGS1bPlJY-CiWsqJrK6aiqWjqvA2PBRsu4tM5bIbCu5hqzDOFZ0_CH5KDt2viYUF02ZZRO1Uj5J7hw4HSV5THwEHhkMiNvdh_eXIywGiaVI1qZUU0G1GSSmkyZkfeom70kQmKnG91maaYVZrirCxGlhSukHQjjplkTpHO2DjAJnZGXqFmDoBctdtUs7bbvzaezb-YY7ERg4ssy8noSajrQsbfTIQV4K8TJmkkeziRhVfr58M6AzOQVevPXhjPyYj-MT2KnWxu7Lcgg-k8CQszIo9He9u8tcFu4LIqM6Jklzj7MfKRd_UiY4SUrIF-p1JP_z-spucXS-hA5qw7JwbDZxmeQdQ3ueVpafwCwLCyU priority: 102 providerName: ProQuest |
| Title | Synbiotic-driven modulation of the gut microbiota and metabolic functions related to obesity: insights from a human gastrointestinal model |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40289100 https://www.proquest.com/docview/3201535125 https://www.proquest.com/docview/3195800486 https://pubmed.ncbi.nlm.nih.gov/PMC12034176 https://doaj.org/article/3b904e5a3b9242859382fd5bba9d8748 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96Ivgifls9lyiCD1KuzVdb327ljlPwkD0PFl9C0qRrwW1l2324f8G_2pm0u2zxwRdfWmimkGQm80FmfkPIW2-TsuB4q-usjYVyJi6U5LHILPdZynwRst2_XKqLa_F5KZcHrb4wJ2yABx427oTbIhFeGniDNUF0rpxVTlprCpdnIpT5gs3bBVPj_UEGcdeuRCZXJx1oYYXJtjJOeAFTSSdmKKD1_62TD4zSNGHywAKdPyD3R9eRng5Tfkhu-eYRuTs0k7x5TH5f3TS2bmEwdhvUYXTdurE5F20rCp4eXW17uq4H7KXeUNM4uvY9yMHPuqRo4oIU0lDg4h3tW9oOjQM-0LrpMI7vKBakUENDcz-6Ml2_aRFzAlQFzi501nlCrs_Pvn28iMdOC3EJHlMfW5lXGKyWTOWy9EIJI7Iqs7lXWSFtmTvGnPGGcWlsaYTAiJrn6F-IklUVf0qOmrbxzwnN0yr10qoCm_0JLiyoW2W4d9w57pmMyPvdxutfA6CGDoFIrvTAJg1s0oFNOo3IHHmzp0Qw7PABRESPIqL_JSIReYOc1Qh30WA-zcpsu05_ulroU5ATgS4vi8i7kahqgcelGcsTYFWIkDWhPJ5Qwnksp8M7AdKjPug0Bz9LcnCuYP2v98P4J-a4Nb7dAg3i_gQIxIg8G-Rtv26BF8JpkkQkn0jiZGOmI039I6CFpywBTyVTL_7HVr4k91g4RSJm2TE56jdb_wq8st7OyO1smc3InfnZ5dfFLBxHeC7m3_8Aay44Ng |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF6VIgQviBtDgQWBeEBW7T18ICFUjiqlxwNtpbxtd73rEInYJXaE8hf4MfxGZtZOqIXEW58iZSfReuf2zsxHyEtnoiLneKtrjQlFYnWYJ5KHIjXcpTFzua92PzxKRqfiy1iON8jvVS8MllWubKI31LYu8B35NgdPJTm4J_n-_EeIqFF4u7qC0OjEYt8tf0LK1rzb-wT8fcXY7ueTj6OwRxUIC4gO2tDIrMTErGBJJgsnEqFFWqYmc0maS1NkljGrnWZcalNoITB75Bn6UlGwsuTwv1fIVXC8ESZ76Xid4MUpZHurxpws2W7A9idY4ivDiOdwAPHA-XmMgH89wQVXOCzTvOD3dm-Rm33ASnc6CbtNNlx1h1zrICyXd8mv42VlpjUshnaOlpPOattDgtG6pBBf0smipbNpN_Gp1VRXls5cC9L3fVpQdKxe9qlvq3GWtjWtO7iCt3RaNfj2oKHYBkM19ZCCdKKbdl7jpAswULg7j-dzj5xeCifuk82qrtxDQrO4jJ00SY4Qg4ILA0Y-0dxZbi13TAbkzerg1Xk3xkP59CdLVMcmBWxSnk0qDsgH5M2aEkdw-y_q-UT1Gq24ySPhpIZPCHNwbFzGSiuN0bmFTWQBeYGcVThko8IqnoleNI3aO_6qdkBOBAbaLCCve6KyBh4Xum-KgKfCuVwDyq0BJViBYri8EiDVW6FG_dWZgDxfL-MvsbKucvUCaHDakB-8GJAHnbytn1vgNXQcRQHJBpI4OJjhSjX95meUxyyC-ChNHv1_X8_I9dHJ4YE62Dvaf0xuMK8rImTpFtls5wv3BCK-1jz1akbJ2WXr9R_zdmjb |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synbiotic-driven+modulation+of+the+gut+microbiota+and+metabolic+functions+related+to+obesity%3A+insights+from+a+human+gastrointestinal+model&rft.jtitle=BMC+microbiology&rft.au=Mok%2C+Kevin&rft.au=Tomtong%2C+Putsawee&rft.au=Ogawa%2C+Takuma&rft.au=Nagai%2C+Kenshiro&rft.date=2025-04-27&rft.issn=1471-2180&rft.eissn=1471-2180&rft.volume=25&rft.issue=1&rft.spage=250&rft_id=info:doi/10.1186%2Fs12866-025-03953-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2180&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2180&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2180&client=summon |